Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01410240 · ClinicalTrials.gov registry record · Phase 4
Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty
A Phase 4 study, sponsored by Baxter Healthcare Corporation.
- Completed
- Registry status
- Phase 4
- Development phase
- 137
- Enrollment target
NCT01410240 is a Phase 4 study that has completed, run by Baxter Healthcare Corporation. The registered enrollment target is 137 participants.
The verdict
NCT01410240, a Phase 4 study, has completed, sponsored by Baxter Healthcare Corporation.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 137 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the efficacy and safety of FLOSEAL to standard of care for hemostasis in subjects undergoing total knee arthroplasty.
Interventions
- PROCEDURE Standard of Care
- DRUG FLOSEAL Hemostatic Matrix + Standard of care
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2011-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01410240
The ClinicalTrials.gov registry entry for NCT01410240 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxter Healthcare Corporation, which has 46 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Standard of Care is the first listed.
NCT01410240 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01410240 about?
NCT01410240 is a clinical study titled "Efficacy and Safety of FLOSEAL for Hemostasis in Total Knee Arthroplasty". The purpose of this study is to compare the efficacy and safety of FLOSEAL to standard of care for hemostasis in subjects undergoing total knee arthroplasty.
What is the current status of trial NCT01410240?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 137 participants. The study started on 2011-09. Estimated completion is 2013-01.
What interventions are being tested in trial NCT01410240?
The interventions under investigation include: Standard of Care (PROCEDURE), FLOSEAL Hemostatic Matrix + Standard of care (DRUG).
Who is sponsoring clinical trial NCT01410240?
This trial is sponsored by Baxter Healthcare Corporation, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.